Zachary C. Howard

Array ( [id] => 17022327 [patent_doc_number] => 20210246198 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/149540 [patent_app_country] => US [patent_app_date] => 2021-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19660 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17149540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18244216 [patent_doc_number] => 20230076527 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA [patent_app_type] => utility [patent_app_number] => 17/791194 [patent_app_country] => US [patent_app_date] => 2021-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -132 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18244216 [patent_doc_number] => 20230076527 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA [patent_app_type] => utility [patent_app_number] => 17/791194 [patent_app_country] => US [patent_app_date] => 2021-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -132 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16962915 [patent_doc_number] => 20210214414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => RECOMBINANT ROBO2 PROTEINS, COMPOSITIONS, METHODS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/125903 [patent_app_country] => US [patent_app_date] => 2020-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17125903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19058991 [patent_doc_number] => 11938185 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Treatment of headache, migraine and/or photophobia conditions using humanized anti-PACAP antibodies [patent_app_type] => utility [patent_app_number] => 17/122243 [patent_app_country] => US [patent_app_date] => 2020-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 157 [patent_no_of_words] => 105251 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17122243 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18168427 [patent_doc_number] => 20230035037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => TEIPP PEPTIDE VARIANT AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/780398 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18168427 [patent_doc_number] => 20230035037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => TEIPP PEPTIDE VARIANT AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/780398 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170398 [patent_doc_number] => 20210324068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => USE OF ANTI-PACAP ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF FOR TREATMENT, PREVENTION, OR INHIBITION OF PHOTOPHOBIA [patent_app_type] => utility [patent_app_number] => 16/953443 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65861 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16953443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17104386 [patent_doc_number] => 11124582 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-21 [patent_title] => FLT3L-FC fusion proteins [patent_app_type] => utility [patent_app_number] => 16/951458 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 92705 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18126250 [patent_doc_number] => 20230011870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => NANOVACCINE FOR HEART FAILURE [patent_app_type] => utility [patent_app_number] => 17/777335 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13345 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17777335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18747091 [patent_doc_number] => 11806382 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-07 [patent_title] => Methods of inhibiting integrin a9b1 activity [patent_app_type] => utility [patent_app_number] => 16/951650 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 20 [patent_no_of_words] => 19340 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17007105 [patent_doc_number] => 20210238266 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => COMPOSITIONS AND METHODS FOR ANTI-LYST IMMUNOMODULATION [patent_app_type] => utility [patent_app_number] => 17/098076 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20040 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17098076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18240764 [patent_doc_number] => 20230073075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => HUMAN HENDRA VIRUS AND NIPAH VIRUS ANTIBODIES AND METHODS OF USE THEREFOR [patent_app_type] => utility [patent_app_number] => 17/776337 [patent_app_country] => US [patent_app_date] => 2020-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47781 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17776337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18078754 [patent_doc_number] => 20220404366 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => ANTI-CLEVER-1 AGENTS FOR CONTROLLING THE EXPRESSION OF CELL SURFACE MARKERS ON LEUCOCYTES, AND USING THESE TO GUIDE ANTI-CLEVER-1 BASED CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 17/775354 [patent_app_country] => US [patent_app_date] => 2020-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7211 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17185232 [patent_doc_number] => 20210332117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => METHODS FOR INHIBITING MYOSTATIN ACTIVATION BY ADMINISTERING ANTI-PRO/LATENT MYOSTATIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/083917 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68628 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17083917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657454 [patent_doc_number] => 20210054090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/080626 [patent_app_country] => US [patent_app_date] => 2020-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17080626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214545 [patent_doc_number] => 20210347882 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => ANTIBODIES TO HUMAN RESISTIN [patent_app_type] => utility [patent_app_number] => 17/077433 [patent_app_country] => US [patent_app_date] => 2020-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9812 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17077433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126233 [patent_doc_number] => 20210301001 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => ANTIBODY THAT BINDS MURINE WISE PROTEIN [patent_app_type] => utility [patent_app_number] => 17/071931 [patent_app_country] => US [patent_app_date] => 2020-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050920 [patent_doc_number] => 20240092889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => AN ANTIBODY, A PHARMACEUTICAL COMPOSITION, AND A METHOD [patent_app_type] => utility [patent_app_number] => 17/768053 [patent_app_country] => US [patent_app_date] => 2020-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17768053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050920 [patent_doc_number] => 20240092889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => AN ANTIBODY, A PHARMACEUTICAL COMPOSITION, AND A METHOD [patent_app_type] => utility [patent_app_number] => 17/768053 [patent_app_country] => US [patent_app_date] => 2020-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17768053 [rel_patent_id] =>[rel_patent_doc_number] =>)